APOBEC3D/F Polyclonal Antibody BT-AP00526
Specifications
| 20ul / 50ul / 100ul |
Background:
APOBEC3F is a member of the cytidine deaminase gene family. It is one of seven related genes or pseudogenes found in a cluster, thought to result from gene duplication, on chromosome 22. Members of the cluster encode proteins that are structurally and functionally related to the C to U RNA-editing cytidine deaminase APOBEC1. It is thought that the proteins may be RNA editing enzymes and have roles in growth or cell cycle control. Alternatively spliced transcript variants encoding different isoforms have been identified.
Classification:
Primary antibody
Alternative names:
APOBEC3D; Probable DNA dC->dU-editing enzyme APOBEC-3D; APOBEC3F; DNA dC->dU-editing enzyme APOBEC-3F; Apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3F
Species reactivity:
Human;Monkey
Host:
Rabbit
Isotype:
IgG
Immunogen:
The antiserum was produced against synthesized peptide derived from human APOBEC3D/F. AA range:232-281
Concentration:
1 mg/ml
Molecular weight:
46598
Applications:
WB, IHC-p, ELISA
Storage:
-20°C for one year
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.